Yale team develops drug therapy via proteasomes

Most drugs have to remain bound to their target in order to maintain their effect, which means large doses are required to keep enough targets blocked, increasing the likelihood of side effects. “Twenty-one years ago, I set out to develop a different paradigm,” says Craig Crews, a biochemist at Yale University.

The PROTACs that Crews and his colleagues have developed are designed to co-opt cells’ natural quality-control machinery — the proteasome.